Experience the Most Targeted Prostate
Cancer Treatment:

Intraoperatively Planned LDR Prostate Brachytherapy at Western Radiation Oncology

LDR brachytherapy with palladium-103 is the most targeted and precise form of radiation therapy available to treat your prostate cancer – Precise, Effective, and Minimally Invasive Radiation Therapy with Palladium-103 Intraoperatively Planned Brachytherapy Leads to Better Outcomes.

Why Choose LDR Brachytherapy with Palladium-103 for Prostate Cancer Treatment?

When facing a prostate cancer diagnosis, choosing the right treatment is crucial for achieving the best possible outcome. LDR (Low Dose Rate) brachytherapy with palladium-103 is a precise form of radiation therapy that offers unparalleled precision in targeting and treating prostate cancer cells, while minimizing damage to surrounding healthy tissues and organs.

LDR brachytherapy involves the insertion of tiny, radioactive seeds directly into the prostate gland. These seeds emit a continuous, low dose of radiation over several weeks, gradually destroying cancer cells while minimizing harm to nearby structures. Palladium-103, a radioactive isotope with a short half-life, ensures that radiation is delivered in a controlled and targeted manner.

By opting for LDR brachytherapy with palladium-103, you’ll benefit from:

Highly targeted treatment

When done with intraoperative real-time adaptive planning, LDR brachytherapy can deliver millimeter level precision and accuracy to sculpt the radiation dose to your specific anatomy and "dose-escalate" to areas of concern while minimizing radiation dose to surrounding tissues

Shorter treatment duration

Conventional radiation therapy may require daily sessions for several weeks, while LDR brachytherapy is a one-time outpatient procedure

Lower risk of complications

The precision of LDR brachytherapy leads to fewer side effects and a reduced risk of complications, such as urinary incontinence and erectile dysfunction.

Minimally invasive procedure

The vast majority of men return to their normal lives the day after the procedure with minimal to no pain or discomfort

High Long Term Disease-Free Cure Rates


low to intermediate risk
prostate cancer


low to intermediate risk
prostate cancer

DOUBLES cure rate for patients with high risk prostate cancer,
as compared to conventional external beam radiation therapy alone.

1 According to the largest international study of 1597 patients receiving Pd-103 implants across the world. Tang, Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study, Radiotherapy & Oncology 2023

2 According to the ASCENDE-RT trial (Morris, International Journal of Radiation Oncology, Biology, and Physics, 2017), brachytherapy boost increased the biochemical progression-free-survival rates from 62% at 9 years to 83% at 9 years. More modern studies using intraoperative planning techniques, such as the TRIP randomized trial in Japan (presented in 2023), show a 9-year progression-free-survival rate of 90% for patients with high risk prostate cancer who receive a brachytherapy boost.

Low Rate of Side Effects

Sexual function

Urinary Function

Gastrointestinal function

Protects sexual function, with lower rates of erectile dysfunction, extremely low rates (1%) of long term grade 3 urinary side effects, and rare gastrointestinal side effects1

1 The PROTECT randomized trial as well as several other studies have shown that brachytherapy has the lowest rate of erectile dysfunction rates of all active standard of care treatment options for localized prostate cancer. The TRIP randomized trial, which used modern intraoperative planning techniques, showed a low 1% risk of long term grade 3 urinary or bowel side effects.

Fast Recovery Time

Same day outpatient procedure

Procedure time:
30 minutes

Back to normal activities next day

Our Expert Team of Physicians

Physicians at Western Radiation Oncology have completed over 7,000 cases of prostate
brachytherapy and currently perform more than 700 a year – more than any other
physician group doing palladium brachytherapy in the world per year

Dr. Steve Kurtzman, MD
Dr. Kurtzman is a national leader in the advent of intraoperatively planned prostate brachytherapy. He has taught physicians across the United States his technique since the 1990s and served on medical advisory boards for multiple companies in the prostate brachytherapy space

Learn More

Dr. Ankit Agarwal, MD
Dr. Ankit Agarwal has treated patients with prostate brachytherapy across California, Arizona, and North Carolina. He also published extensively on the treatment of prostate cancer and specializes in the use of intraoperatively planned prostate brachytherapy

Learn More


WRO is a multi-physician, multi-location cancer treatment practice specializing in advanced, targeted radiation therapy for prostate cancer.